Most cited papers from Eli Lilly (United States)

Eli Lilly (United States)

What are the most cited papers from Eli Lilly (United States)?

The most cited paper from Eli Lilly (United States) is "The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease" (Guy M. McKhann, David S. Knopman, Howard Mark Chertkow et al., 2011), with 19,132 citations. Next come "NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease" (10,885) and "Biological insights from 108 schizophrenia-associated genetic loci" (8,181).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 1,397 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Guy M. McKhann, David S. Knopman, Howard Mark Chertkow et al. · Alzheimer s & Dementia Open access	22 Apr 2011	19,132
2	NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease Clifford R. Jack et al. · Alzheimer s & Dementia Open access	Apr 2018	10,885
3	Biological insights from 108 schizophrenia-associated genetic loci Stephan Ripke et al. · Nature Open access297 authors	Jul 2014	8,181
4	Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Reisa Anne Sperling et al. · Alzheimer s & Dementia Open access	22 Apr 2011	7,286
5	Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes Stephen D. Wiviott, Eugene Braunwald, Carolyn H. McCabe et al. · New England Journal of Medicine Open access	4 Nov 2007	6,822
6	Serum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans Robert V. Considine, Madhur K. Sinha, Mark L. Heiman et al. · New England Journal of Medicine	Feb 1996	6,381
7	Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis Gordon R. Bernard, Jean‐Louis Vincent, Pierre‐François Laterre et al. · New England Journal of Medicine Open access	8 Mar 2001	6,170
8	A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1 Yoshio Miki et al. · Science	7 Oct 1994	6,134
9	Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis Robert M. Neer, Claude D. Arnaud, José Zanchetta et al. · New England Journal of Medicine	10 May 2001	4,604
10	Depression Is a Risk Factor for Noncompliance With Medical Treatment M. Robin DiMatteo, Heidi S. Lepper, Thomas W. Croghan · Archives of Internal Medicine	24 Jul 2000	4,215
11	Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial John Dormandy et al. · The Lancet Open access	Oct 2005	4,157
12	The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity Frederick Wolfe, Daniel Joseph Clauw, Mary‐Ann Fitzcharles et al. · Arthritis Care & Research Open access	23 Feb 2010	3,990
13	Ghrelin induces adiposity in rodents Matthias H. Tschöp, David L. Smiley, Mark L. Heiman · Nature	Oct 2000	3,964
14	Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics Fariborz Mohamadi, Nigel G. J. Richards, Wayne C. Guida et al. · Journal of Computational Chemistry	May 1990	3,774
15	Tirzepatide Once Weekly for the Treatment of Obesity Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad et al. · New England Journal of Medicine Open access	4 Jun 2022	3,648
16	How to improve R&D productivity: the pharmaceutical industry's grand challenge Steven M. Paul, Daniel S. Mytelka, Christopher T. Dunwiddie et al. · Nature Reviews Drug Discovery Review	19 Feb 2010	3,579
17	The World Health Organization adult ADHD self-report scale (ASRS): a short screening scale for use in the general population Ronald C. Kessler, Lenard A. Adler, Minnie Ames et al. · Psychological Medicine	21 Jan 2005	3,497
18	Membrane transporters in drug development Kathleen M. Giacomini et al. · Nature Reviews Drug Discovery ReviewOpen access	Mar 2010	3,373
19	A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). Chris J. Vlahos, William F. Matter, K. Y. Hui et al. · Journal of Biological Chemistry Open access	Feb 1994	3,267
20	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Hertzel C. Gerstein et al. · The Lancet Open access1,458 authors	9 Jun 2019	3,173
21	The Prevalence and Correlates of Adult ADHD in the United States: Results From the National Comorbidity Survey Replication Ronald C. Kessler, Lenard A. Adler, Russell A. Barkley et al. · American Journal of Psychiatry	Apr 2006	2,910
22	Donanemab in Early Symptomatic Alzheimer Disease John Randall Sims et al. · JAMA Open access309 authors	17 Jul 2023	2,880
23	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017 Christina Fitzmaurice et al. · JAMA Oncology Open access628 authors	27 Sep 2019	2,699
24	mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt Kathryn E O'Reilly, F. Rojo, Qing‐Bai She et al. · Cancer Research Open access	Feb 2006	2,599
25	Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein Dora Games et al. · Nature	Feb 1995	2,521
26	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial Hansjochen Wilke, Kei Muro, Eric Van Cutsem et al. · The Lancet Oncology	17 Sep 2014	2,505
27	Cytochrome P-450 Polymorphisms and Response to Clopidogrel Jessica L. Mega, Sandra L. Close, Stephen D. Wiviott et al. · New England Journal of Medicine Open access	22 Dec 2008	2,503
28	A systematic review of the associations between dose regimens and medication compliance Ami J. Claxton, Joyce A. Cramer, Courtney Pierce · Clinical Therapeutics Review	Aug 2001	2,403
29	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes Răzvan Cristescu et al. · Nature Medicine	20 Apr 2015	2,299
30	Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial Charles S. Fuchs et al. · The Lancet Open access	2 Oct 2013	2,223
31	Generalized Additive Models: An Introduction With R Alan Y. Chiang · Technometrics	Aug 2007	2,199
32	Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Peter M. Kuehl, Jiong Zhang, Yvonne Lin et al. · Nature Genetics	Apr 2001	2,173
33	FGF-21 as a novel metabolic regulator Alexei Kharitonenkov, Tatiyana L. Shiyanova, Anja Köester et al. · Journal of Clinical Investigation Open access	3 May 2005	2,126
34	Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects Leslie M. Shaw, Hugo Vanderstichele, Malgorzata Elzbieta Knapik-Czajka et al. · Annals of Neurology Open access	19 Mar 2009	2,124
35	Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals Harry M. Olson, Graham R. Betton, Denise E. Robinson et al. · Regulatory Toxicology and Pharmacology	Aug 2000	2,056
36	Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Juan P. Frías, Melanie J. Davies, Julio Rosenstock et al. · New England Journal of Medicine Open access	25 Jun 2021	2,029
37	Circulating Ghrelin Levels Are Decreased in Human Obesity Matthias H. Tschöp, Christian Weyer, Pietro Antonio Tataranni et al. · Diabetes Open access	Apr 2001	2,012
38	Design and Analysis of Experiments Gary R. Sullivan · Journal of Quality Technology	1998	1,887
39	TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model Yaming Wang, Marina Cella, Kaitlin Mallinson et al. · Cell Open access	26 Feb 2015	1,836
40	The OARSI histopathology initiative – recommendations for histological assessments of osteoarthritis in the mouse S.S. Glasson, M.G. Chambers, Wim B. van den Berg et al. · Osteoarthritis and Cartilage Open access	22 Sep 2010	1,785
41	Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection Antonio F. Pardiñas et al. · Nature Genetics Open access	25 Feb 2018	1,748
42	The Distribution and Mechanism of Action of Ghrelin in the CNS Demonstrates a Novel Hypothalamic Circuit Regulating Energy Homeostasis Michael Alexander Cowley et al. · Neuron Open access	Feb 2003	1,687
43	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial Andrew Xiuxuan Zhu et al. · The Lancet Oncology	18 Jan 2019	1,680
44	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia Willemijn J. Jansen et al. · JAMA Open access129 authors	19 May 2015	1,662
45	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders Sebastian Palmqvist et al. · JAMA Open access	28 Jul 2020	1,657
46	Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women Pierre Dominique Delmas, Nina H. Bjarnason, Bruce Mitlak et al. · New England Journal of Medicine Open access	4 Dec 1997	1,651
47	The principal features and mechanisms of dopamine modulation in the prefrontal cortex Jeremy Keith Seamans, Charles R. Yang · Progress in Neurobiology	Sep 2004	1,626
48	Detailed analysis of grid‐based molecular docking: A case study of CDOCKER—A CHARMm‐based MD docking algorithm Guosheng Wu, D. H. Robertson, Charles L. Brooks et al. · Journal of Computational Chemistry	30 Jul 2003	1,575
49	Key green chemistry research areas—a perspective from pharmaceutical manufacturers David J. C. Constable, Peter J. Dunn, John D. Hayler et al. · Green Chemistry	2007	1,554
50	The role of neuropeptide Y in the antiobesity action of the obese gene product Thomas W. Stephens, Margret B. Basinski, Pamela K. Bristow et al. · Nature	Oct 1995	1,514

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.